Pharmacy & Therapeutics - March 2009 - (Page 115) NEW Indication TREANDA is now FDA approved for indolent non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen Also indicated for patients with chronic lymphocytic leukemia (CLL) For more information, visit www.TREANDA.com TREANDA is indicated for the treatment of patients with indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. TREANDA is indicated for the treatment of patients with CLL. Efficacy relative to first-line therapies other than chlorambucil has not been established. The most serious adverse reactions associated with TREANDA in clinical trials were myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions, and other malignancies. Please see accompanying brief summary of Prescribing Information. ©2008 Cephalon, Inc. All rights reserved. TRE146 November 2008 http://www.TREANDA.com http://www.TREANDA.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.